Arrowhead Reports Key Updates on REDEMPLO and Phase III Trials for Q2 2026 Earnings Call
During Arrowhead's (ARWR) Q2 2026 earnings call, the company highlighted strong prescription growth of its drug REDEMPLO in the U.S., geographic expansion into key markets like Canada and Australia, and progress on Phase III trials for SHTG. The updated wholesale pricing to $45,000 per patient annually positions it as a premium offering.
Tickers: $ARWR